Related Experiment Video
Updated: May 25, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
QTc prolongation assessment in anticancer drug development: clinical and methodological issues
G Curigliano1, G Spitaleri, F de Braud
1Division of Medical Oncology, European Institute of Oncology, I.R.C.C.S., Milan, Italy.
Ecancermedicalscience
|January 26, 2012
Summary
Assessing cardiac safety, particularly QT interval prolongation, is crucial for new cancer drugs. Current risk management strategies for non-cardiac drugs may not suit oncology, necessitating refined approaches for patient safety and drug development.
Area of Science:
- Cardiology
- Oncology
- Clinical Pharmacology
Background:
- Cardiac safety assessments, especially QT interval prolongation, are vital in oncology drug development.
- QTc prolongation poses risks like torsades de pointes and sudden cardiac death.
- Existing risk management for QTc prolongation is based on non-life-threatening, chronic conditions, potentially unsuitable for acute cancer treatments.
Purpose of the Study:
- To review clinical and methodological issues in QTc prolongation assessment for oncology drugs.
- To highlight limitations in Phase I trial design for oncology drug development.
- To advocate for refined risk management strategies in oncology drug development.
Main Methods:
- Review of clinical and methodological issues related to QTc prolongation assessment.
- Discussion of limitations in Phase I oncology drug development.
- Analysis of current risk management strategies and their applicability to oncology.
Main Results:
- Current QTc risk management methodologies may not be appropriate for oncology drugs due to differences in disease and treatment duration.
- There is a lack of specific guidelines for managing cardiac safety in oncology drug development.
- QTc assessment significantly impacts clinical trial conduct, patient eligibility, dosing, and development decisions.
Conclusions:
- Refined strategies are needed for QTc prolongation risk management in oncology to avoid negatively impacting patient access and development of novel cancer treatments.
- Collaborative efforts between oncologists, cardiologists, and regulatory agencies are essential for developing appropriate risk management plans for oncology agents with cardiac safety concerns.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...